Corrigendum to "Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis" [EClinicalMedicine 55 (2022) 101795]

Abstract

[This corrects the article DOI: 10.1016/j.eclinm.2023.101904.][This corrects the article DOI: 10.1016/j.eclinm.2022.101795.].

Corrected Figure 3

Mean Incidences of Adverse Events by Cancer Type. A, Mean incidences of all grade adverse events by cancer type. B, Mean incidences of grade 3 or higher adverse events by cancer type. C, Mean incidences of serious adverse events by cancer type. D, Mean incidences of adverse events that resulted in drug discontinuation by cancer type. For both panels, values to the left of the line are lower than the mean, to the right, higher. CrI, Bayesian credible intervals.

Corrected Figure 4

Mean Incidences of Adverse Events by Drug Type. A, Mean incidences of all grade adverse events by drug and dose. B, Mean incidences of grade 3 or higher adverse events by drug and dose. C, Mean incidences of serious adverse events by drug and dose. D, Mean incidences of adverse events that resulted in drug discontinuation by drug and dose. E, Comparisons of mean incidences of adverse events between different drugs and dose. CrI, Bayesian credible intervals.